Advertisement

Topics

Latest "MissionCelogos is a biotechnology company" News Stories

11:52 EDT 17th July 2018 | BioPortfolio

Here are the most relevant search results for "MissionCelogos is a biotechnology company" found in our extensive news archives from over 250 global news sources.

More Information about MissionCelogos is a biotechnology company on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about MissionCelogos is a biotechnology company for you to read. Along with our medical data and news we also list MissionCelogos is a biotechnology company Clinical Trials, which are updated daily. BioPortfolio also has a large database of MissionCelogos is a biotechnology company Companies for you to search.

Showing "MissionCelogos biotechnology company" News Articles 1–25 of 20,000+

Tuesday 17th July 2018

Venture Verde and the Chicago Mushroom Company to Open a Controlled Environment Agricultural Facility in Chicago

Facility to Help Drive New Sustainability Standards for Indoor Urban Farming Venture Verde, a real estate, land and water management company focused on driving sustainability, announced it signed an agreement with the


One of Nation’s Largest Home-Based Care Providers to Rebrand as “Elara Caring”

Following the Combination of Great Lakes Caring, National Home Health Care, and Jordan Health Services, Unified Company Adopts New Name and Branding Today, the newly formed company that combines Great Lakes Caring, National Home Health Care, and Jordan Health Services announced it will be named Elara Caring. In April, these three award-winning health c...

Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 2018

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will h...


Saladax Submits for FDA Review a Rapid Blood Test for Levels of Risperidone

Saladax is Advancing Personalized Medicine by Providing Doctors with the Diagnostic Tools to Treat Patients Better Saladax Biomedical Inc., a diagnostics company providing kits to test drug blood levels for adherence and personalized dose management, on July 3 submitted a De Novo classification request to the U.S. Food and Drug Administration (FDA) for...

The Official US Launch of Biolon OVD (Ophthalmic Viscosurgical Device) for Use in Cataract Surgery

Amring Pharmaceuticals Inc. (Amring), a generic pharmaceutical company, today announced the release of its latest product, Biolon OVD (Ophthalmic Viscosurgical Device). Amring is excited to offer this device to position itself in the growing ophthalmic market with the introduction of Biolon OVD. Biolon OVD is a fermentation-based, sterile, optical...

Independent/Provider-Sponsored Administrative Costs Accelerated in 2017

Independent/Provider-Sponsored health plans had administrative cost increases of 5.5% in 2017, the highest since 2013. Last year’s increase was 2.4%. Increases are calculated for continuously participating plans, after backing out the effect of mix changes. On an as-reported basis, per member costs grew by 5.2% compared with 3.0% in the prior ye...

Global Medical REIT Inc. Schedules 2018 Second Quarter Financial Results Conference Call

Conference Call Scheduled for Wednesday, August 8, 2018 at 9:00 a.m. ET Global Medical REIT Inc. (NYSE:GMRE) (the “Company”), a Maryland corporation engaged primarily in the acquisition of licensed, state-of-the-art, purpose-built healthcare facilities and the leasing of these facilities to strong clinical operators with leading market share, ...

American Shared Hospital Services Selects PCG Advisory Group for Investor Relations and Strategic Communications

American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced that it has retained PCG Advisory Group, a leading investor relations and digital strategies firm, to serve as an advisor for investor relations and strategic c...

Eureka Therapeutics Announces that Boehringer Ingelheim is Exercising an Option to License Novel TCR Mimic (TCRm) Antibodies

Eureka Therapeutics Inc. announced today that Boehringer Ingelheim has elected to exercise an option for the exclusive license of novel human TCR-mimicking (TCRm) antibodies against an undisclosed target to be used for the potential development and commercialization of therapies for cancer patients. The licensed TCRm antibodies were developed under a resea...

Moderna Opens New Manufacturing Site in Norwood, MA

200,000 Square Foot State-of-the-Art Plant Built to Support Development of mRNA Medicines Moderna Therapeutics, a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the opening of its state-of-the-art manufacturing facility i...

Blade Therapeutics Announces Initiation of Phase 1 Study of Lead Calpain Inhibitor BLD-2660 for Fibrosis

Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the initiation of a Phase 1 clinical trial for its lead compound, BLD-2660. The first-in-human Phase 1, placebo controlled, dose escalation trial is evaluating the safety and pharmacokinetics (PK) profile of orally administered BLD-2660, a sele...

Jamieson Wellness Inc. Announces Date of Second Quarter 2018 Financial Results and Conference Call

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the Company will release its second quarter 2018 financial results after the market close on Wednesday, August 8, 2018. The Company will host a conference call for investors at 5:00 p.m. Eastern Time to discuss the second quarter 2018 results. The call ca...

TripleCare Brings Physician-Based Telemedicine Services to Commonwealth Care of Roanoke

Services to Roll out in all 12 Commonwealth Care Locations; Three Initially in the 2018 Third Quarter with Nine to be Completed by Year-end TripleCare, a national provider of telemedicine-based healthcare to the post-acute care sector, including skilled nursing facilities (SNFs), announced today the Company will introduce its services across all

D2 Consulting Highlights Seven Key Factors Impacting Value-Based Contracting Between Health Plans/PBMs and Pharmaceutical or Medical Device Manufacturers

D2 Consulting, a leading healthcare consulting firm providing strategic leadership and tactical market implementation for life science, biotech and medical device manufacturers, cites the importance of value-based contracting for healthcare technologies to gain better coverage with health plans and pharmacy benefit managers (PBMs). The transition away ...

Sunovion to Launch Take On Tomorrow™ Giving Opportunity with Red Sox Foundation and 7th Annual Community Service Program

Expecting to Reach 25,000 Cumulative Employee Volunteer Hours This Summer, Company Will Mark Milestone by Donating $25,000 to Support Education and Mental Health Initiatives Sunovion Pharmaceuticals Inc. (Sunovion), a partner of the Boston Red Sox, today announced that the Company is continuing its a

Arcus Biosciences Announces Final Safety Results From Phase 1 Trial for AB928 in Healthy Volunteers

- AB928 was safe and well tolerated at all doses evaluated - - Safety and pharmacodynamic data from healthy volunteer trial support selection of dose for evaluation of AB928 in combination with anti-PD-1 therapy in patients - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer i...

Sirona Biochem Corp SBM Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14032018] Prices from USD $250

SummarySirona Biochem Corp Sirona Biochem is a biotechnology company that discovers and develops therapeutics, cosmeceuticals and biological ingredients. The company develops drugs for diabetes and cancer. It offers cosmeceutical programs such as development of antiaging and depigmenting agents, biological ingredients and inducers and adjuvant for biological development. Sirona Biochem offers prod...

Labcyte to Support GP-write Project Under New Agreement With Center of Excellence for Engineering Biology

Researchers Will Receive Preferred Pricing and Early Access to New Technologies for Understanding the Blueprint for Life Provided by the Human Genome Project (HGP-read) Labcyte Inc. today announced an agreement with the Center for Excellence in Engineering Biology (CEEB), an independent nonprofit that is managing

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union

Novel Enzyme Replacement Therapy in Development for Treatment of ENPP1 Deficiency Inozyme Pharma (Inozyme), a biopharmaceutical company dedicated to developing treatments for rare and debilitating diseases, today announced that both the Food and Drug Administration’s (FDA) Office of Orphan Products Development and the Eu

22nd Century Announces the Immediate Feasibility of the FDA’s Nicotine Reduction Plan

Reynolds American and Phillip Morris unable to comply with the FDA’s plan “for 20-years” 22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, yesterday responded to the Advance Notice of Proposed Rulemaking (

Arkivum Continues to Expand Presence in North America, Scaling Its Boston Hub

Arkivum are continuing to expand and have achieved a number of key milestones over the last 6 months including the recently announced release of its new Arkivum version 5 technology stack. A testament to Arkivum’s expansion is our growing footprint in North America, which has led to the establishment of a Boston hub located in the Financial Dist...

Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction

-- Nicotine Addiction Planned as First Indication -- Omeros Corporation (NASDAQ: OMER) today announced that the first cohort of subjects has been dosed in the Company’s Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in Omeros’ OMS527 program broadly targeting addictions and compulsive disorders. Inhibitor...

Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug

Erectile dysfunction market is estimated to reach $3.2 billion by 2022 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have ...

Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation

Gamida Cell, a leading cellular and immune therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for NiCord as a treatment for hematopoietic stem cell transplantation (HSCT). Gamida Cell was previously granted orphan drug designation for NiCord by the FDA as a treatment fo...

Co-Diagnostics Completes Submission of CE Mark Registration for Tuberculosis Screening Test

Company’s Logix Smart™ MTB Test to be available for purchase with CE mark in August 2018 Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ MTB Test technical file has been submitted for registra...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks